Summary:
New medication Amvuttra (vutrisiran) introduced in Portugal.
Significant improvement in treatment for paramyloidosis, known as 'little feet disease'.
Infarmed confirms the launch, enhancing care for patients.
New Hope for Patients with Paramyloidosis
The treatment for paramyloidosis, commonly referred to as 'little feet disease', has received an important boost in Portugal with the introduction of a new medication, Amvuttra (vutrisiran). This announcement was made today by Infarmed, the National Authority for Medicines and Health Products.
Photo: Maria João Gala / Archive
This new medication promises to enhance the quality of life for those affected by this rare condition, providing hope to many families across the country. The introduction of Amvuttra is expected to significantly improve treatment outcomes and manage symptoms more effectively than previous options.
Comments
Join Our Community
Create an account to share your thoughts, engage with others, and be part of our growing community.